文献速递外周动脉疾病

间歇性跛行患者接受血运重建与药物治疗的长期患者报告结局

Long-term patient-reported outcomes among patients undergoing revascularization vs medical therapy for intermittent claudication.
PubMed 文献 · J Vasc Surg · 2024-04-10

本研究纳入2016至2021年在学术医疗中心血管外科门诊评估的225例间歇性跛行患者,比较血运重建(40%,n=89)与非手术最佳药物治疗(60%,n=136)与患者报告结局的关系。中位随访5.2±1.6年(最长6.9年)后,两组PROMIS-PF无显著差异;非手术组PROMIS-SA随时间改善的可能性高于血运重建组(校正P=0.045)。

要点

  • 间歇性跛行患者血运重建与非手术治疗后PROMIS-PF无显著差异(P=0.07)。
  • 非手术组PROMIS-SA随时间改善优于血运重建组(校正P=0.045)。
  • 作者认为这些发现支持对间歇性跛行患者进行保守长期管理。

核心结论

  • 间歇性跛行患者无论接受血运重建还是继续非手术治疗,功能状态和活动满意度相关的患者报告结局在长达7年内相似,这些发现支持保守长期管理。

研究设计与样本

  • 在学术医疗中心血管外科门诊识别2016至2021年因间歇性跛行首次评估的患者,按随访期间是否接受血运重建 vs 继续非手术药物和推荐运动治疗分组,使用线性混合效应模型分析治疗方式与PROMIS-PF、PROMIS-SA及踝肱指数随时间的关系,并对重复观察进行聚类,模型校正年龄、性别、糖尿病、Charlson合并症指数、临床衰弱评分、吸烟和基线踝肱指数。

主要发现

  • 共225例间歇性跛行患者,40%(n=89)接受血运重建(42%旁路手术,58%外周血管介入),60%(n=136)继续非手术治疗。
  • 随访最长6.9年,平均随访5.2±1.6年。
  • 血运重建组更可能有临床衰弱(P=0.03)、基线踝肱指数更低(0.55±0.24 vs 0.72±0.28;P<0.001)、基线PROMIS-PF评分更低(36.72±8.2 vs 40.40±6.73;P=0.01)。
  • 校正协变量后,两组PROMIS-PF的组间差异、时间趋势及组间随时间差异均无统计学显著性(P=0.07、P=0.13、P=0.08)。
  • 所有间歇性跛行患者PROMIS-SA随时间显著增加(校正P=0.019),非手术组PROMIS-SA随时间改善的可能性高于血运重建组(校正P=0.045)。

临床怎么用

  • 作者认为这些发现支持对间歇性跛行患者进行保守长期管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Society for Vascular Surgery guidelines recommend revascularization for patients with intermittent claudication (IC) if it can improve patient function and quality of life. However, it is still unclear if patients with IC achieve a significant functional benefit from surgery compared with medical management alone. This study examines the relationship between IC treatment modality (operative vs nonoperative optimal medical management) and patient-reported outcomes for physical function (PROMIS-PF) and satisfaction in social roles and activities (PROMIS-SA). METHODS: We identified patients with IC who presented for index evaluation in a vascular surgery clinic at an academic medical center between 2016 and 2021. Patients were stratified based on whether they underwent a revascularization procedure during follow-up vs continued nonoperative management with medication and recommended exercise therapy. We used linear mixed-effect models to assess the relationship between treatment modality and PROMIS-PF, PROMIS-SA, and ankle-brachial index (ABI) over time, clustering among repeat patient observations. Models were adjusted for age, sex, diabetes, Charlson Comorbidity Index, Clinical Frailty Score, tobacco use, and index ABI. RESULTS: A total of 225 patients with IC were identified, of which 40% (n = 89) underwent revascularization procedures (42% bypass; 58% peripheral vascular intervention) and 60% (n = 136) continued nonoperative management. Patients were followed up to 6.9 years, with an average follow-up of 5.2 ± 1.6 years. Patients who underwent revascularization were more likely to be clinically frail (P = .03), have a lower index ABI (0.55 ± 0.24 vs 0.72 ± 0.28; P < .001), and lower baseline PROMIS-PF score (36.72 ± 8.2 vs 40.40 ± 6.73; P = .01). There were no differences in patient demographics or medications between treatment groups. Examining patient-reported outcome trends over time; there were no significant differences in PROMIS-PF between groups, trends over time, or group differences over time after adjusting for covariates (P = .07, P = .13, and P =.08, respectively). However, all patients with IC significantly increased their PROMIS-SA over time (adjusted P = .019), with patients managed nonoperatively more likely to have an improvement in PROMIS-SA over time than those who underwent revascularization (adjusted P = .045). CONCLUSIONS: Patient-reported outcomes associated with functional status and satisfaction in activities are similar for patients with IC for up to 7 years, irrespective of whether they undergo treatment with revascularization or continue nonoperative management. These findings support conservative long-term management for patients with IC.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Holeman TA, Chester C, Hales JB, et al. Long-term patient-reported outcomes among patients undergoing revascularization vs medical therapy for intermittent claudication. J Vasc Surg. 2024. PMID: 38608965. doi:10.1016/j.jvs.2024.03.455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。